US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX)
(LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2
diabetes and early-stage chronic kidney disease, announces that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the
kidneyintelX.dkd test. These claims were filed under US Patent Application No. 16/671.256 by the Joslin Diabetes Center and this patent is exclusively licensed to Renalytix.
KidneyintelX.dkd received Food and Drug Administration de Novo marketing authorization on June 29, 2023.
The newly allowed claims further strengthen the core intellectual property underpinning the KidneyIntelX technology by directly incorporating sTNFR1 and sTNFR2 into a set of consolidated claims directed towards identifying risk of early kidney function decline, thereby enabling therapeutic strategies for those at increased risk of progressive decline.
The Company believes this development reflects the Renalytix strategy of innovation in biomarker research, development and translation in collaboration with the Joslin Diabetes Center and other leading research partners globally. When taken together with other key milestones, such as FDA De Novo marketing authorization, broad insurance coverage and published clinical utility and outcomes data, Renalytix believes this increases its competitive advantage. The Company also believes this creates further barriers to entry in the large addressable market for optimizing clinical management of kidney disease to drive improved patient outcomes. A similar strategy to protect Renalytix’s intellectual property is being pursued in Europe, which also presents a large opportunity for KidneyIntelX expansion.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | ||
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Shalin Bhamra | ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | |
CapComm Partners | ||
Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com | |
Lesen Sie auch
About Chronic Kidney Disease